Insider Trading Alert - LQDT, REG And REGN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 31, 2014, 69 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,500.00 to $189,613,554.86.

Highlighted Stocks Traded by Insiders:

Liquidity Service (LQDT) - FREE Research Report

Mateus-Tique Jaime who is Director at Liquidity Service bought 15,000 shares at $24.76 on March 31, 2014. Following this transaction, the Director owned 188,262 shares meaning that the stake was reduced by 8.66% with the 15,000-share transaction.

The shares most recently traded at $26.84, up $2.08, or 7.75% since the insider transaction. Historical insider transactions for Liquidity Service go as follows:

  • 4-Week # shares sold: 12,278
  • 12-Week # shares sold: 12,278
  • 24-Week # shares sold: 12,278

The average volume for Liquidity Service has been 503,700 shares per day over the past 30 days. Liquidity Service has a market cap of $842.4 million and is part of the services sector and retail industry. Shares are up 14.96% year-to-date as of the close of trading on Monday.

Liquidity Services, Inc. operates online auction marketplaces for sellers and buyers of surplus, salvage, and scrap assets in the United States. The company has a P/E ratio of 21.1. Currently there are 6 analysts that rate Liquidity Service a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LQDT - FREE

TheStreet Quant Ratings rates Liquidity Service as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, poor profit margins and a generally disappointing performance in the stock itself. Get the full Liquidity Service Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regency Centers Corporation (REG) - FREE Research Report

Thompson James D. who is Managing Director at Regency Centers Corporation sold 2,000 shares at $51.00 on March 31, 2014. Following this transaction, the Managing Director owned 46,860 shares meaning that the stake was reduced by 4.09% with the 2,000-share transaction.

The shares most recently traded at $50.96, down $0.04, or 0.08% since the insider transaction. Historical insider transactions for Regency Centers Corporation go as follows:

  • 4-Week # shares sold: 16,500
  • 12-Week # shares sold: 17,500
  • 24-Week # shares sold: 26,515

The average volume for Regency Centers Corporation has been 489,500 shares per day over the past 30 days. Regency Centers Corporation has a market cap of $4.7 billion and is part of the financial sector and real estate industry. Shares are up 10.28% year-to-date as of the close of trading on Monday.

Regency Centers Corporation operates as a real estate investment trust. The company, through its subsidiaries, owns, operates, and develops community and neighborhood shopping centers that are tenanted by grocers, category-leading anchors, specialty retailers, and restaurants. The stock currently has a dividend yield of 3.72%. The company has a P/E ratio of 73.3. Currently there are 5 analysts that rate Regency Centers Corporation a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REG - FREE

TheStreet Quant Ratings rates Regency Centers Corporation as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Regency Centers Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Sanofi who is 10% Owner at Regeneron Pharmaceuticals bought 613,890 shares at $308.87 on March 31, 2014. Following this transaction, the 10% Owner owned 19.7 million shares meaning that the stake was reduced by 3.21% with the 613,890-share transaction.

The shares most recently traded at $312.00, up $3.13, or 1% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares sold: 17,000

The average volume for Regeneron Pharmaceuticals has been 1.1 million shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $29.4 billion and is part of the health care sector and drugs industry. Shares are up 9.1% year-to-date as of the close of trading on Monday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 87.4. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Sinks for Eighth Straight Session; Intel's CEO Departs -- ICYMI

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins